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Abstract
Preventive treatment for those most at risk of heart disease rather than those with the 
highest blood pressure or cholesterol values may be a more efficacious strategy for 
disease man agreement. This depends on accurate biomarker-based risk assessment 
tools. An evidence-based model of heart disease risk was developed using the 
Framingham model with an additional five risk factors, including three of the newer 
blood biomarkers. This was applied to the adult population of the 3rd National Health 
and Nutrition Examination Survey cohort. Addition ally, the selection criteria for 
therapeutic intervention from the Adult Treatment Panel III guidelines (for 
hyperlipidemia) and the 7th Report of the Joint National Committee (for hypertension) 
were applied to the same subjects. Of this cohort 54% qualified for at least one of these 
medications while 18% qualified for both. Using this 18% cutoff, the 18% of the sub 
jects with the highest calculated heart disease risk were also identified using the 
developed risk model. We applied established therapeutic reductions in heart disease 
probability to those identified by guidelines and to those identified by risk. Applying 
both drugs to the high-risk group (one third the size of the guidelines group) achieved 
the same reduction in population risk (about one fourth) as applying the drugs to the 
guideline groups and required only half as many prescriptions. Intermediate results 
were found when an intervention group was identified by a combination of both high 
risk and high levels of risk factors. In this simulation, identifying patients by heart 
disease risk level resulted in substantially fewer people being treated with fewer drugs 
and achieving a similar reduction in disease risk. 
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ABSTRACT 
Preventive treatment for those most at risk of heart disease rather than those with the high 
est blood pressure or cholesterol values may be a more efficacious strategy for disease man 
agement. This depends on accurate biomarker-based risk assessment tools. An evidence-based 
model of heart disease risk was developed using the Framingham model with an additional 
five risk factors, including three of the newer blood biomarkers. This was applied to the adult 
population of the 3rd National Health and Nutrition Examination Survey cohort. Addition 
ally, the selection criteria for therapeutic intervention from the Adult Treatment Panel III 
guidelines (for hyperlipidemia) and the 7th Report of the Joint National Committee (for hy 
pertension) were applied to the same subjects. Of this cohort 54% qualified for at least one 
of these medications while 18% qualified for both. Using this 18% cutoff, the 18% of the sub 
jects with the highest calculated heart disease risk were also identified using the developed 
risk model. We applied established therapeutic reductions in heart disease probability to those 
identified by guidelines and to those identified by risk. Applying both drugs to the high-risk 
group (one third the size of the guidelines group) achieved the same reduction in population 
risk (about one fourth) as applying the drugs to the guideline groups and required only half 
as many prescriptions. Intermediate results were found when an intervention group was iden 
tified by a combination of both high risk and high levels of risk factors. In this simulation, 
identifying patients by heart disease risk level resulted in substantially fewer people being 
treated with fewer drugs and achieving a similar reduction in disease risk.  
INTRODUCTION 
ORONARY  HEART  DISEASE  (CHD) is a preva
lent, expensive, and preventable disease,
and is a major focus of disease management or 
ganizations. Evidence based guidelines for the 
prevention of CHD have been developed and 
updated from time-to-time by national organi- 
 
zations. The National Cholesterol Education 
Program recently promulgated the third ver 
sion of the Adult Treatment Plan (ATP III) 
guidelines1 for the treatment of hyperlipi 
demia. The Seventh Report of the Joint Na 
tional Committee on hypertension treatment 
(JNC7) was released in 2003.2 These guidelines 
are not entirely intended for the prevention of 
heart disease directly but for the reduction of 
subclinical risk factors. Thus, action levels of LDL 
cholesterol and blood pressure are presented 
and not, primarily, scores from such risk as 
sessment tools as the Framingham heart dis 
ease model. Several authors have suggested 
changes that would incorporate more risk- 
based assessments.3–6 Several British societies 
combined their recommendations for risk fac 
tor intervention around risk assessments,7 and 
several American authors have suggested the 
same for American recommendations.8,9 The 
ATP III guidelines now include the Framing 
ham score as a secondary criteria. 
Disease management is most successful for 
those conditions in which future suffering and 
costs can be lowered through efficacious self- 
care efforts. Disease management also works 
most effectively when supporting a physician’s 
plan of care. Disease management thus rests on 
the twin pillars of accurate identification of 
those at risk of future suffering and cost, and 
of cost-effective intervention for those identi 
fied individuals. Thus, medical costs in a whole 
population can be managed by working with a 
small subgroup at highest risk. For example, 
this cost-effectiveness recently has been shown 
for the drug treatment of a series of conditions 
traditionally under disease management.10 
This type of care must involve collaborative 
practice models that include physicians in pa 
tient self-management education, particularly 
in compliance with drug therapies for which 
there is no immediate visible benefit. 
The benefits of preventive programs are 
most observable and cost-effective among 
those at highest risk.11–15 There are differences 
of opinion about how to assess this risk. Some 
suggest age alone,14 whereas others suggest 
preexisting disease.11,15 Yet others suggest 
more complex risk analysis such as with the 
Framingham heart disease risk score4,13 or with 
additional newer risk factors.12,16,17 It is im 
portant to note that most of these risk factors 
are not modifiable. In fact, the results of the 
large statin drug trials show minimal effect dif 
ferences between patient subgroups defined by 
non-modifiable risk factors. For example, in the 
Heart Protection Study, a 25% drop in risk was 
fairly consistent whether or not a person had a 
preexisting condition.18 In a pooled analysis of 
pravastatin trials, only subgroups based on hy- 
pertension or LDL level had modest subgroup 
effects. Among those groups defined by non- 
modifiable risk factors (age, diabetes, gender, 
etc), there were no differences. This suggests 
that treatment lowers risk by a fixed percent in 
a population independent of the sources of that 
risk.15 This is not only a convenient product of 
the mathematical nature of logistic risk models 
but also is a clinical reality that can be the ba 
sis of a new paradigm in cardiovascular dis 
ease prevention.14 While the relative reduction 
in risk may be constant across the range of dis 
ease risk, the absolute reduction in events is 
markedly different in high and low risk groups. 
This concentration of a large number of future 
events in the high risk stratum makes this 
group an especially appealing target by which 
to lower the absolute number of events in the 
population relatively cost effectively. 
Within the disease management context, re- 
ducing disease costs for a population is 
achieved by working most intensively with 
those at highest risk of future disease and the 
associated cost. Thus, making the most accu 
rate identification of those at truly highest risk 
would be of paramount importance. Since 1991 
when the Framingham model was published in 
its present form,19 many new biological risk 
factors of heart disease have been discov 
ered.20–22 Combining these with the Framing- 
ham model would produce an advanced and 
credible prediction tool for CHD risk.16,17 For 
example, three studies have specifically shown 
how C-reactive protein would supplement the 
Framingham score in identifying those at high 
risk.23–25 
We have developed such a tool and use it to 
demonstrate, in a representative population, 
the benefits of prescribing CHD preventive 
measures by risk level rather than by risk fac- 
tor levels. 
MATERIALS AND METHODS 
Applying guidelines to NHANES III 
The 3rd National Health and Nutrition Ex 
amination Survey (NHANES III) is a nation- 
wide  weighted  survey  of  individuals  in  the 
United States performed between 1988 and 
1994. The results of the survey were used in 
their unweighted form to assess the perfor- 
mance of the ATP III and JNC7 guidelines. 
Adult subjects aged 40–75, inclusive, were 
used. The following variables were assessed for 
inclusion in the eligible group for ATP III: LDL 
cholesterol, age, gender, history of CHD and 
diabetes, current smoking, and a family history 
of CHD. The NHANES III family history ques- 
tion identified those whose parents had a heart 
attack before the age of 50 while the ATP III 
family history question identifies a mother 
with heart disease before age 65 or a father be 
fore age 55. This difference may result in fewer 
people being identified at high risk than if the 
ATP III definition was used. The remaining 
variables used in the Framingham score19 were 
used: systolic blood pressure, total cholesterol, 
HDL cholesterol, and left ventricular hypertro 
phy. In addition several newer risk factors were 
added: lipoprotein(a), C-reactive protein, ho- 
mocysteine, and subjective assessment of exer 
cise level (three levels). The JNC7 also required 
diastolic blood pressure. Using these variables, 
the guidelines of ATP III and JNC7 were ap 
plied with particular attention to those for 
whom drug therapy was recommended. 
Creation of CHD risk model 
The Framingham CHD risk score is a well- 
known and validated tool for assessing future 
CHD risk. Our goal was to add to this model 
the newer risk factors in such a way that the 
credibility of the Framingham model would be 
retained while adding newer risk information. 
The novel method for the creation of this ex- 
tended risk model has been termed “synthesis 
analysis” and has been demonstrated in a sim- 
plified clinical context.26 Here is the method in 
brief. The age and gender-adjusted odds ratios 
or relative risks for novel risk factors are de 
termined from published meta-analyses or 
from our own meta-analyses of the epidemio- 
logic literature. These new risk factors are 
added in a stepwise fashion to the existing 
model (starting with Framingham) adjusting 
for the colinearity between the added variable 
and the existing model at each step. The dataset 
utilized in this process is from NHANES III. 
First, the 5-year probability of CHD is calcu 
lated among the adult NHANES subjects using 
the Framingham risk equation. Then a linear 
regression model is run comparing that prob- 
ability against the first added variable, in this 
case family history. The beta for family history 
was 0.088 which is a measure of the colinear- 
ity between the added variable and the previ- 
ous variables. This value is subtracted from the 
univariate beta from the medical literature 
(0.262) to obtain the beta used for family his- 
tory in the stepwise model (0.0174). The re- 
sulting logistic model after this step contains 
the Framingham variables and family history 
with a beta of 0.0174. In the next step, a new 
variable is adjusted by a similar subtraction 
and added to the model. When all the candi- 
date variables are entered, or cannot be added 
due to excessive colinearity, then the model is 
complete. For a summary of the univariate and 
stepwise multivariate adjusted odds ratios 
used in the model, see Table 1. 
Our current model includes the following 
variables in addition to those in the Framing- 
ham model: prior CHD diagnosis, lipopro- 
tein(a), C-reactive protein, homocysteine, as 
sessment of exercise level, and family history 
of CHD. The addition of a prior CHD diagno 
sis as a risk factor was done following the cal 
culation of first and subsequent CHD risk for 
the Framingham cohort.27 For the remaining 
additional variables a relative risk per unit of 
measure of the risk factor was calculated, then 
each was modified and added in a stepwise 
fashion (Table 1). The lipoprotein(a) relative 
risk of 1.15 per log unit of mg/dL was derived 
from a meta-analysis by Danesh et al.28 The C- 
reactive protein relative risk of 1.175 per log 
unit of mg/L was derived from another 
Danesh meta-analysis.29 The homocysteine rel 
ative risk of 1.042 per µ,mole/L was derived 
from a recent meta-analysis by D.S. Wald et 
al.30 The relative risk for a family history of 
CHD came from a study from Framingham31 
and the relative risk for three subjective steps 
of exercise came from a review of Powell et al.32 
Effects of therapeutic agents 
A meta-analysis by the Blood Pressure Low- 
ering Treatment Trialists’ Collaboration found 
TABLE 1.   ORIGINAL RELATIVE RISKS AND STEP-WISE MULTIVARIATE ADJUSTED RELATIVE
RISKS FOR VARIABLES IN THE COMPLETE CHD RISK ASSESSMENT MODEL
TABLE 2.   DESCRIPTION OF NHANES III ADULT SUBJECTS BEFORE SIMULATED TREATMENT
BY ATP III AND JNC7 GUIDELINES, BY CHD RISK ALONE, OR BY A COMBINATION
Variables Guidelines Risk Combination 
aMean of logarithm-transformed variable. 
Risk factors Units 
Original 
relative risk 
Multivariate 
relative risk 
CHD family history No = 0; yes = 1 1.30 1.19 
Exercise 3 levels 0.72 0.85 
Logarithm of C-Reactive Protein mg/L 1.58 1.11 
Homocysteine µ,mol/L 1.042 1.036 
Logarithm of Lipoprotein(a) mg/dL 1.15 1.12 
that, in general, antihypertensives reduce CHD 
events by 19%.33 A meta-analysis by LaRosa et 
al in 199934 concluded that statins as a group 
lowered major CHD events by 31%. The calcu- 
lated combined effect of the two medications 
together would be a 44% reduction in CHD. 
RESULTS 
Restricting the final dataset to those for 
whom all the variables were available and for 
the  ages  used  in  the  original  Framingham 
study, limited the age range to 40–75 and the 
total number to 2890. The subjects, in their 
treatment groups, are described in Table 2. Of 
these subjects with complete data, 30% were el- 
igible for cholesterol treatment by ATP III and 
42% were eligible for hypertension treatment 
by JNC7 (Table 3). Thus, 54% of the population 
was eligible for one or both treatments, and 
18% were eligible for both. When CHD risk was 
used as the criteria, the 18% of the subjects with 
the highest risk were eligible for both medica- 
tions. The remaining subjects received no treat 
ment. 
N 2890 1556 518 799 
Age 56 59 64 62 
Female (%) 54 52 35 45 
Prior CHD (%) 5 8 18 13 
Diabetes (%) 11 18 29 22 
Family history CHD (%) 7 7 8 6 
Smokers (%) 28 31 45 36 
Exercise (1–3) 2.1 2.1 2.0 2.0 
Systolic BP 131 141 143 145 
Albumin (mg/dL) 4.0 4.0 3.9 3.9 
Lipoprotein(a)a  (mg/dL) 11 11 22 17 
Fibrinogen (mg/dL) 312 324 376 353 
Total cholesterol (mg/dL) 216 228 229 237 
HDL cholesterol (mg/dL) 50 48 42 45 
C-Reactive Proteina  (mg/dL) 3.6 4.0 6.0 4.9 
Homocysteine  (µ,mol/L) 10 11 12 11 
When the estimated risk reductions were ap- 
plied to the appropriate groups, the reduction 
of risk when treating by the guidelines was 
27%, and from a group average risk of 6.2% in 
5 years to 4.6%. A similar risk reduction of 27% 
was found when the treated group was identi- 
fied by CHD risk level (Fig. 1). Thus, when us 
ing CHD risk rather than the guidelines in 
guiding therapy, one third of the number of pa 
tients with roughly one half as many prescrip 
tions were needed and the CHD risk reduction 
was an equivalent amount. 
Those eligible for treatment by the guidelines 
were combined by the number of prescriptions 
for which they were eligible: 0, 1, or 2. These 
groups were compared with the CHD risk- 
based eligibility (Table 4). Less than half of the 
subjects who met the eligibility of both sets of 
guidelines qualified as high-risk subjects (232 
of 518). Conversely, 12% of the high-risk group 
qualified for no drugs by the guidelines (60 of 
518). 
An alternative was proposed in which both 
high CHD risk and high levels of risk factors 
were used to identify those eligible for treat 
ment. In addition to those at the top 18% of risk, 
we added those with LDL cholesterol over 190 
mg/dL or those with systolic blood pressure 
over 160 mm Hg or diastolic blood pressure 
over 100 mm Hg (Table 5). Both drug treatment 
groups together comprised 28% of the popula 
tion, compared to 54% by the original guide 
lines and 18% by the original risk algorithm. By 
applying the appropriate drug treatments, the 
CHD risk was lowered 29%, slightly more than 
the other two strategies. The number of treated 
subjects  was  exactly  half  of  the  guidelines 
groups and about two thirds (64%) as many 
prescriptions were needed as in the guidelines 
groups. 
These improvements in treatment efficiency 
by treating by risk are balanced by an increased 
number of probable CHD events in the low 
risk group (Table 6). The risk-defined group 
that receives no treatment is about twice as 
large as the therapeutic non-treated group. 
Since the average CHD risk is about the same 
in these two groups, the number of probable 
events is twice as many (71 versus 35) in the 
low-risk group. This is lowered to 56 probable 
events with the combined non-treated group. 
DISCUSSION 
The idea of prescribing by disease risk is not 
new. N.J. Wald and M.R. Law have forcefully 
put forward this idea15 and implemented it in 
a most austere form in their Polypill concept.14 
Both American and British guidelines now use 
some version of risk assessment.1,7,35 Others 
have shown that using the guidelines can be 
poor predictors of CHD risk.5 
The advantages to disease management or 
ganizations of such a risk-based strategy are ev 
FIG. 1. CHD risk among NHANES III adult subjects at 
baseline and with simulated treatment by ATP III and 
JNC7 guidelines, by CHD risk alone, or by a combination. 
Base, baseline; guide, ATP III and JNC7 guidelines; risk, 
CHD risk alone; comb, combination of risks. 
TABLE 3.   COMPARISON OF HYPERTENSION TREATMENT
ELIGIBILITY BY JNC7 (ROWS) AND CHOLESTEROL
TREATMENT ELIGIBILITY BY ATP III (IN COLUMNS) 
AMONG NHANES III ADULTS
ATP III 
Non-eligible Eligible Total 
JNC7 
Non-
eligible 
Eligible 
Total
1334 
686 
2020 
352 
518 
870 
1686 
1204 
2890 
TABLE 4.   COMPARISON OF NUMBER OF
GUIDELINE TREATMENT ELIGIBILITIES (IN ROWS) 
AND CHD RISK-BASED ELIGIBILITY
(IN  COLUMNS) AMONG  NHANES III ADULTS
CHD risk-based eligibility 
TABLE 6.   COMPARISON OF THE PROBABLE NUMBER OF
CHD EVENTS IN 5 YEARS BY THERAPEUTIC TREATMENT
GROUPS (IN ROWS) AND CHD RISK-BASED TREATMENT
GROUPS (IN COLUMNS) AMONG NHANES III ADULTS
CHD risk-based eligibility 
aThe probable number of events is the sum of the 
probabilities of CHD for the members of each cell from 
Table 3. 
Non-eligible Eligible Total Non-eligible Eligible Total 
Number of treatment 
eligibilities 
Number of treatment 
eligibilities 
0 1274 60 1334 0 24a 11 35 
1 812 226 1038 1 31 47 78 
2 286 232 518 2 16 52 68 
Total 2372 518 2890 Total 71 110 181 
ident from the increased efficiency of treating 
fewer patients with fewer drugs for similar re 
sults. We have made assumptions about the ef 
ficacy of the two large classes of drugs to ar 
rive at our estimates of reduced risk. However, 
even if these drugs are only a fraction as effi 
cacious in clinical practice as in clinical trials, 
the relative benefit of risk-based eligibility is 
the same, though the absolute risk reduction 
and cost containment would be reduced. 
Underidentification and undertreatment still 
treatment,37 although  accurate assessment  of 
coronary risk remains difficult for many doc 
tors.38 Even short visits with doctors and 
nurses are effective in changing lifestyle.39 
However, a recent study in Canada among the 
elderly showed that the probability of statin 
prescription actually decreases with advancing 
40 
remain difficult clinical issues.36  Only half of age and advancing risk. One shortcoming of 
eligible patients have their cholesterol checked, 
and only half of those who meet the guidelines 
are put on the proper therapy. Of those on med- 
ication, three quarters do not reach their ther 
apeutic goal and less than 30% of patients con 
tinue on therapy after a year.36 Knowledge of 
disease risk scores has been shown to improve 
a risk-based approach is that it requires a com 
puter and the time necessary to enter the re- 
quired data. Unfortunately, the utilization of 
the ATP III guidelines is also a very complex 
algorithm that requires substantial patient in- 
formation and is not easily performed in the 
presence of a waiting patient. The decision tree 
derived from ATP III has been computerized 
effectively. 
This reported exercise is a simplification in 
several ways. It does not consider other patho- 
logical sequelae of hypertension and dyslipi 
demia. The guidelines address relatively rare 
conditions such as preeclampsia and obstruc 
tive liver disease that are not addressed in the 
CHD-risk approach. Also, for the purpose of 
this example, we did not consider other im 
portant outcomes such as kidney disease, cere 
bral vascular disease and heart failure. The op 
timal risk-based algorithm would need to be a 
composite of all the deleterious sequelae 
weighted by their severity or cost. We have be 
gun this process by developing other risk mod 
TABLE 5.   COMPARISON OF HYPERTENSION TREATMENT
ELIGIBILITY (IN ROWS) AND CHOLESTEROL TREATMENT
ELIGIBILITY (IN COLUMNS) AMONG NHANES III 
ADULTS DETERMINED BY A COMBINATION OF
HIGH CHD RISK AND HIGH BLOOD
PRESSURE OR HIGH LDL CHOLESTEROL
Cholesterol treatment 
Non-eligible Eligible Total 
Hypertension treatment 
Non-eligible 2091 131 222 
Eligible 136 532 668 
Total 227 663 2890 
 
 
els for these diseases. Another simplification is 
that this was a simulation of outcomes and not 
a study of actual outcomes. Therefore, our dis 
ease risk algorithm was used both to identify 
those at risk and to assess the success of the in 
tervention (Table 6). 
In administering care to a patient, clinicians 
must consider many factors beyond chronic 
disease risk, including adverse effects, com 
pliance, patient preferences and other com 
plicating presenting factors risks.41 Numerous 
options are available to clinicians and not all 
options can be readily quantified. In disease 
management the prevailing findand-treat- 
high-risk paradigm may not necessarily focus 
on the same patients as a clinician. Thus, the 
risk-based tool suggested here may be more ap 
propriately used by a disease management or 
ganization than by a clinician. This type of risk 
assessment and disease management involves 
more collaborative practice models that include 
physician intervention and disease manage 
ment in patient self-management. The bio 
marker-based risk assessment encourages a 
more seamless approach to risk factor man 
agement to reduce incidence of future costly 
diseases. 
The benefit of a biomarker-based risk model 
is that the newest risk factor information can 
be incorporated into the model and a more ac 
curate assessment of risk made. For example, 
the beta used for C-reactive protein was only 
very recently published29 but was used in our 
updated risk model. The three new markers— 
C-reactive protein, lipoprotein(a), and homo- 
cysteine—played a key role in identifying those 
at highest risk. The cost of these markers is an 
added cost not encountered in the guidelines- 
based approach. Another cost of treating so few 
patients with a risk-based treatment plan (only 
18%) is that an increased number of CHD 
events is likely in the larger untreated group. 
However, this increase is more than compen 
sated for by the 44% reduction in CHD events 
in the high-risk group. 
The objective of this simplified simulation 
was to show the potential of a risk-based dis- 
ease management approach. To make this a re- 
ality, more will need to be understood about 
how this process can be integrated into the 
physician’s practice, how multiple disease risks 
can be incorporated, and how to further solve 
the continuing problem of underidentification 
and undertreatment. 
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